Welcome to our dedicated page for Inspira Tech SEC filings (Ticker: IINNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Inspira Technologies Oxy B.H.N. Ltd. (IINNW) provides access to the company’s regulatory disclosures as a foreign private issuer. Inspira files annual reports on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These filings often include or reference press releases that describe product milestones, regulatory clearances, purchase orders, government-related discussions, and financing transactions.
Through its Form 6-K submissions, Inspira reports developments such as FDA 510(k) clearance and Israeli AMAR certification for the INSPIRA ART100 cardiopulmonary bypass system, government and institutional purchase orders for ART100 systems, and updates on the HYLA real-time blood sensor’s progress toward U.S. Food and Drug Administration submission. Other 6-K filings have covered matters like sales agreement amendments, private placements, and the activation of consulting firms to support business initiatives.
On this page, users can review how Inspira describes its INSPIRA ART platform, ART100 system, VORTX oxygenation technology, INSPIRA Cardi-ART device, and HYLA blood sensor within official filings. These documents outline the development status of each technology, including statements that certain products are still being designed and developed, have not been tested or used in humans, and are not yet approved by regulatory entities.
Stock Titan enhances access to these filings with tools that surface key sections and context from lengthy reports, helping readers quickly locate information on topics such as product regulatory status, capital raising activities, and material agreements. Real-time updates from EDGAR ensure that new Inspira Technologies filings, including future 6-Ks and other forms, appear here as they are submitted, alongside any disclosed information on warrants, purchase orders, or other corporate actions.
Inspira Technologies is expanding its U.S. presence by deploying its FDA-cleared INSPIRA™ ART100 system at a new premier New York academic medical center ranked among the state’s top 10 hospitals. The system is being integrated into the hospital’s clinical workflow for a structured commercial evaluation.
The evaluation aims to define clinical protocols and assess potential broader institutional adoption, adding to existing commercial activity at other leading U.S. healthcare facilities. Inspira positions the ART100 as a foundation for its next-generation ART500 awake-oxygenation system and is also advancing its HYLA™ continuous blood monitoring platform.
Inspira Technologies Oxy B.H.N. Ltd. is offering up to $2,015,985 of ordinary shares through an at-the-market program with A.G.P./Alliance Global Partners under its existing $75 million shelf registration.
The ATM facility lets the company sell shares on Nasdaq from time to time at prevailing prices, paying A.G.P. a 3% commission. Shares outstanding were 43,271,837 as of February 17, 2026, and would rise to 46,694,562 if the full amount were sold at $0.589 per share. The company plans to use net proceeds for research and development, regulatory work, commercialization and general corporate purposes.
The filing highlights substantial dilution for new investors, Nasdaq non-compliance with the $1.00 minimum bid price rule, and an auditor’s going concern paragraph, underscoring financing and listing risks alongside the capital raise.
Inspira Technologies OXY B.H.N. Ltd investor Joe Ronen Hayon has reported his ownership stake in the company. He beneficially owns 3,204,010 ordinary shares, representing 7.3% of the class as of December 31, 2025, based on 43,859,838 shares outstanding.
The holding consists of 655,623 ordinary shares, 2,491,228 ordinary shares from vested restricted stock units, and 57,159 ordinary shares issuable upon options exercisable within 60 days of December 31, 2025. He has sole voting and dispositive power over all 3,204,010 shares and no shared power or group relationships are reported.
Joe Ronen Hayon filed an amended Schedule 13G reporting beneficial ownership of 3,204,010 ordinary shares of Inspira Technologies OXY B.H.N. Ltd, representing 7.3% of the class as of December 31, 2025, based on 43,859,838 outstanding ordinary shares.
The holding consists of 655,623 ordinary shares, 2,491,228 ordinary shares vested from restricted stock units, and 57,159 ordinary shares issuable upon option exercise within 60 days of December 31, 2025. Hayon reports sole voting and dispositive power over all 3,204,010 shares and no shared power.
Inspira Technologies Oxy B.H.N. Ltd. received a Nasdaq notice on February 9, 2026 that its ordinary shares are not in compliance with the $1.00 minimum bid price requirement, after trading below that level for 30 consecutive business days.
The notice has no immediate effect on trading, and the shares continue on the Nasdaq Capital Market under symbol IINN. The company has 180 days, until August 10, 2026, for its closing bid price to reach at least $1.00 for ten consecutive business days to regain compliance, with the possibility of a second 180‑day period if additional conditions are met.
If compliance is not restored within the allowed period, Nasdaq may delist the shares. Inspira plans to monitor its share price and consider available options, potentially including a reverse share split, to address the deficiency.
Inspira Technologies reported procedural progress on two previously announced binding purchase orders of $22.5 million and $27 million. The company’s distribution partner notified Inspira that these orders have moved to the final governmental budgetary validation and fund allocation stage within the relevant authorities’ procurement processes.
Approximately 91% of the purchase order value has passed commercial and administrative review and is now in the last budgetary authorization step before funds can be released and operations executed, subject to customary governmental approvals. Inspira reiterated that payment and revenue recognition related to these orders are expected during the 2026 fiscal cycle, in line with the governmental budget cycle and deployment milestones, and noted it has completed internal preparations for execution.
Inspira Technologies Oxy B.H.N. Ltd. submitted a Form 6-K that incorporates by reference previously filed registration statements and furnishes a press release dated September 18, 2025. The press release announces that Inspira will unveil its HYLA™ real-time blood sensor at the U.S. ELSO conference and states the device has 97.35% accuracy confirmed. The filing is signed by Chief Executive Officer Dagi Ben-Noon. The document provides an event announcement and a specific accuracy figure for the product but does not include financial results, commercialization details, regulatory approvals, or timelines.
Inspira Technologies Oxy B.H.N. Ltd. disclosed a press release announcing that its HYLA™ blood sensor achieved 97.35% accuracy. The company states this result as an advance toward a planned FDA submission for clearance, signaling progress in regulatory milestones for the device. The filing incorporates that press release into the Form 6-K report.
The information provided is limited to the accuracy result and the intended regulatory step; no financial results, timelines, trial sizes, or additional performance metrics are included in the filing.
Inspira Technologies OXY B.H.N. Ltd. filed a Form S-8 to register an additional 1,184,910 ordinary shares that may be issued under its Amended and Restated 2019 Equity Incentive Plan. These newly registered shares expand the pool available for future equity awards to employees, directors, and other eligible participants under the plan. The filing follows earlier Form S-8 registrations covering prior share reserves for the same plan and updates certain incorporated documents and exhibits.
Inspira Technologies Oxy B.H.N. Ltd. disclosed a press release dated September 2, 2025 announcing that a top U.S. Honor Roll hospital has expanded clinical use of the company’s INSPIRA™ ART100 system to include lung transplant procedures. The filing reproduces the press release and is signed by Dagi Ben-Noon, Chief Executive Officer. The statement highlights broader clinical adoption of the ART100 device but does not provide revenue, patient counts, contract terms, or trial results in this filing.